Pneumococcal conjugate vaccination schedules in infants —acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study

DiscussionAnalysis will account for potential non-independence of measurements by cluster and so interpretation of effects will be at the individual level (i.e. a population of individuals). PVS-AcqImm will evaluate whether acquisition of vaccine-type pneumococci is reduced by the alternative compared to the standard schedule, which is required if the alternative schedule is to be effective. Likewise, evidence of superior immune response at 18  months of age and safety of PCV co-administration with yellow fever vaccine will support decision-making regarding the use of the alternative 1+1 schedule. Acquisition and immunogenicity outcomes will be essential for the interpretation of the results of the large field trial comparing the two sc hedules.Trial registrationInternational Standard Randomised Controlled Trial Number72821613.
Source: Trials - Category: Research Source Type: clinical trials